Ocular ischemic syndrome - a systematic review.
Terelak-Borys B, Skonieczna K, Grabska-Liberek I.
Med Sci Monit. 2012 Aug;18(8):RA138-144. doi: 10.12659/msm.883260.
Posner-Schlossman syndrome.
Megaw R, Agarwal PK.
Surv Ophthalmol. 2017 May-Jun;62(3):277-285. doi: 10.1016/j.survophthal.2016.12.005. Epub 2016 Dec 22.
Surgical management of secondary glaucoma in Fuchs' heterochromic iridocyclitis.
You YA, Wu Y, Hu S.
Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1785-90. doi: 10.1007/s00417-013-2312-9. Epub 2013 Mar 22.
Iridocyclitis and Secondary Glaucoma.
Macfarlane PB.
Can Med Assoc J. 1941 May;44(5):470-1.
Secondary glaucoma in patients with juvenile rheumatoid arthritis-associated iridocyclitis.
Foster CS, Havrlikova K, Baltatzis S, Christen WG, Merayo-Lloves J.
Acta Ophthalmol Scand. 2000 Oct;78(5):576-9. doi: 10.1034/j.1600-0420.2000.078005576.x.
Fuchs Uveitis Syndrome.
Moshirfar M, Villarreal A, Ronquillo Y.
2024 Feb 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Fuchs heterochromic iridocyclitis-associated glaucoma: a retrospective comparison of primary Ahmed glaucoma valve implantation and trabeculectomy with mitomycin C.
Esfandiari H, Loewen NA, Hassanpour K, Fatourechi A, Yazdani S, Wang C, Yaseri M, Pakravan M.
F1000Res. 2018 Jun 22;7:876. doi: 10.12688/f1000research.15244.2. eCollection 2018.
[Treatment of Acanthamoeba keratitis].
Marchenko NR, Kasparova EA.
Vestn Oftalmol. 2016;132(5):110-116. doi: 10.17116/oftalma20161325110-116.
Treatment of Complications Due to Fuchs Heterochromic Iridocyclitis (FHI) - a Case Report.
Adilovic M, Kalabic M, Cabric A, Becirovic D.
Acta Inform Med. 2022 Jun;30(2):129-132. doi: 10.5455/aim.2022.30.129-132.
The outcome of initial mitomycin C-augmented trabeculectomy with subconjunctival bevacizumab in the management of secondary glaucoma associated with Fuchs heterochromic iridocyclitis.
Elgin U, Sen E, Ozdemir K, Ozdal P, Berker N.
Int Ophthalmol. 2020 Apr;40(4):795-802. doi: 10.1007/s10792-019-01240-3. Epub 2019 Dec 3.
